

Hiroyoshi Nishikawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/748261/publications.pdf>

Version: 2024-02-01

136
papers

17,314
citations

44069

48
h-index

16183

124
g-index

143
all docs

143
docs citations

143
times ranked

23755
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. <i>Gastroenterology</i> , 2022, 162, 799-812.	1.3	28
2	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
3	Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. <i>Cancer Cell</i> , 2022, 40, 201-218.e9.	16.8	266
4	Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 383-387.	1.3	5
5	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	7.0	62
6	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. <i>Cell Reports</i> , 2022, 38, 110331.	6.4	45
7	Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. <i>Life Science Alliance</i> , 2022, 5, e202101230.	2.8	16
8	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	5.3	18
9	The ratio of CD8+ lymphocytes to tumor-infiltrating suppressive FOXP3+ effector regulatory T cells is associated with treatment response in invasive breast cancer. <i>Discover Oncology</i> , 2022, 13, 27.	2.1	10
10	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. <i>Haematologica</i> , 2022, 107, 2418-2431.	3.5	14
11	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 3480-3488.	7.0	8
12	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	1.7	2
13	Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization. <i>STAR Protocols</i> , 2022, 3, 101557.	1.2	3
14	Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. <i>International Immunology</i> , 2021, 33, 39-48.	4.0	4
15	A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients. <i>International Journal of Hematology</i> , 2021, 113, 473-479.	1.6	0
16	HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR TKIs. <i>Thoracic Cancer</i> , 2021, 12, 631-642.	1.9	14
17	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. <i>Scientific Reports</i> , 2021, 11, 341.	3.3	17
18	Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. <i>New England Journal of Medicine</i> , 2021, 384, 42-50.	27.0	40

#	ARTICLE	IF	CITATIONS
19	Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance. <i>International Journal of Hematology</i> , 2021, 113, 772-774.	1.6	1
20	Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion. <i>Experimental and Molecular Medicine</i> , 2021, 53, 202-209.	7.7	51
21	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	17
22	CD4 ⁺ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	47
23	Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP ⁺ regulatory T cells. <i>International Immunology</i> , 2021, 33, 435-446.	4.0	14
24	Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. , 2021, 9, e002591.		105
25	Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies. <i>International Immunology</i> , 2021, 33, 551-562.	4.0	20
26	Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. , 2021, 9, e002279.		19
27	A mixture-of-experts deep generative model for integrated analysis of single-cell multiomics data. <i>Cell Reports Methods</i> , 2021, 1, 100071.	2.9	47
28	TAS-116 (Pimipitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). <i>Clinical Cancer Research</i> , 2021, 27, 6709-6715.	7.0	20
29	Antitumour immunity regulated by aberrant ERBB family signalling. <i>Nature Reviews Cancer</i> , 2021, 21, 181-197.	28.4	141
30	Vescimonas gen. nov., Vescimonas coprocola sp. nov., Vescimonas fastidiosa sp. nov., Pusillimonas gen. nov. and Pusillimonas faecalis sp. nov. isolated from human faeces. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2021, 71, .	1.7	21
31	CYBERTRACK2.0: zero-inflated model-based cell clustering and population tracking method for longitudinal mass cytometry data. <i>Bioinformatics</i> , 2021, 37, 1632-1634.	4.1	1
32	Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 5904.	3.7	3
33	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. <i>Science Immunology</i> , 2021, 6, eabc6424.	11.9	64
34	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. <i>Nature Communications</i> , 2021, 12, 7280.	12.8	11
35	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. <i>Nagoya Journal of Medical Science</i> , 2021, 83, 827-840.	0.3	6
36	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. <i>International Immunology</i> , 2020, 32, 273-281.	4.0	10

#	ARTICLE	IF	CITATIONS
37	Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	58
38	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	7.0	44
39	The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4069-4082.	5.2	76
40	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. <i>Nature Immunology</i> , 2020, 21, 1346-1358.	14.5	431
41	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , 2020, 11, 578848.	4.8	11
42	Endoscopic Activity and Serum TNF- α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1669-1681.	1.9	8
43	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 893-903.	5.3	20
44	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. <i>Immunity</i> , 2020, 53, 187-203.e8.	14.3	119
45	Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. <i>Science Immunology</i> , 2020, 5, .	11.9	160
46	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). <i>Journal of Clinical Oncology</i> , 2020, 38, 2053-2061.	1.6	469
47	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 69-76.	5.3	45
48	A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6614-6622.	7.0	106
49	Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	27.6	872
50	Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. <i>Cancer Science</i> , 2019, 110, 2080-2089.	3.9	614
51	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 165-174.	3.8	123
52	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 4808-4819.	7.0	66
53	PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9999-10008.	7.1	655
54	Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1490-1496.	0.7	15

#	ARTICLE	IF	CITATIONS
55	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. <i>Journal of Experimental Medicine</i> , 2019, 216, 2701-2713.	8.5	82
56	Model-based cell clustering and population tracking for time-series flow cytometry data. <i>BMC Bioinformatics</i> , 2019, 20, 633.	2.6	10
57	Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 609-618.	7.1	141
58	<i>Internal Medicine</i> , 2019, 108, 430-437.	0.0	0
59	Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients. <i>Blood</i> , 2019, 134, 192-192.	1.4	0
60	Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy. <i>Blood</i> , 2019, 134, 1792-1792.	1.4	0
61	Editors' Choice Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. <i>Nagoya Journal of Medical Science</i> , 2019, 81, 1-18.	0.3	18
62	Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis. <i>Cancer Immunology Research</i> , 2018, 6, 378-388.	3.4	35
63	Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 835-844.	2.5	7
64	Regulatory T cells: a potential target in cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1417, 104-115.	3.8	184
65	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. <i>International Immunology</i> , 2018, 30, 13-22.	4.0	74
66	Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumonia. <i>Lung Cancer</i> , 2018, 126, 162-169.	2.0	2
67	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
68	Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. <i>Haematologica</i> , 2018, 103, 1835-1842.	3.5	59
69	Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4106-4106.	1.6	14
70	Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. <i>Scientific Reports</i> , 2017, 7, 43201.	3.3	14
71	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 3-27.	1.1	48
72	Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 1517-1523.	1.8	48

#	ARTICLE	IF	CITATIONS
73	Regulatory T cells, as a target in anticancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 623-627.	2.0	9
74	ICOS ⁺ Foxp3 ⁺ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with <i>Helicobacter pylori</i> . <i>International Journal of Cancer</i> , 2017, 140, 686-695.	5.1	100
75	Possible Biomarker for immune checkpoint inhibitor. <i>Annals of Oncology</i> , 2017, 28, ix20.	1.2	0
76	Suppression from beyond the grave. <i>Nature Immunology</i> , 2017, 18, 1285-1286.	14.5	10
77	Regulatory-T cells (Tregs) in tumor infiltrating lymphocytes (TILs) from patients with advanced gastric cancer (AGC) after chemotherapy containing ramucirumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15570-e15570.	1.6	0
78	Regulatory T cells as a target of cancer immunotherapy. <i>Annals of Oncology</i> , 2016, 27, vii3.	1.2	0
79	Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. <i>PLoS ONE</i> , 2016, 11, e0160576.	2.5	15
80	Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. <i>Blood</i> , 2016, 128, 2083-2088.	1.4	279
81	Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia. <i>Cancer Immunology Research</i> , 2016, 4, 644-649.	3.4	23
82	Two FOXP3 ⁺ CD4 ⁺ T cell subpopulations distinctly control the prognosis of colorectal cancers. <i>Nature Medicine</i> , 2016, 22, 679-684.	30.7	641
83	Roles of regulatory T cells in cancer immunity. <i>International Immunology</i> , 2016, 28, 401-409.	4.0	412
84	Analysis of CCR4-expressing T cells in patients with rhododendrol-induced leukoderma. <i>Journal of Dermatological Science</i> , 2016, 84, e13.	1.9	0
85	Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. <i>Cancer Science</i> , 2016, 107, 189-202.	3.9	6
86	Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein Microarray. <i>Transplantation Direct</i> , 2016, 2, e118.	1.6	9
87	Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 ⁺ Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia. <i>Cancer Immunology Research</i> , 2016, 4, 136-145.	3.4	20
88	Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patients. <i>Blood</i> , 2016, 128, 4240-4240.	1.4	0
89	Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes. <i>Blood</i> , 2016, 128, 4577-4577.	1.4	0
90	Overview: New Modality for Cancer Treatment. <i>Oncology</i> , 2015, 89, 33-35.	1.9	5

#	ARTICLE	IF	CITATIONS
91	Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 ^{high} regulatory T cells in humans. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7225-7230.	7.1	164
92	Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clinical Cancer Research, 2015, 21, 4327-4336.	7.0	187
93	Regulatory T cells in cancer; can they be controlled?. Immunotherapy, 2015, 7, 843-846.	2.0	3
94	Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells. Blood, 2015, 126, 2219-2219.	1.4	2
95	Detection of self-reactive CD8 ⁺ T cells with an anergic phenotype in healthy individuals. Science, 2014, 346, 1536-1540.	12.6	162
96	Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation. Immunity, 2014, 41, 1040-1051.	14.3	450
97	Regulatory T cells in cancer immunotherapy. Current Opinion in Immunology, 2014, 27, 1-7.	5.5	612
98	Comprehensive exploration of autoantibody in Behçet's disease: A novel autoantibody to claudin-1, an essential protein for tight junctions, is identified. Joint Bone Spine, 2014, 81, 546-548.	1.6	1
99	Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science, 2014, 346, 363-368.	12.6	86
100	Induction of CD8 T cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NYESO-1 (NYESO-1 91-110) peptide. International Journal of Cancer, 2013, 132, 345-354.	13.1	27
101	Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature, 2013, 500, 232-236.	27.8	2,339
102	Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17945-17950.	7.1	556
103	Antibody-based therapy in colorectal cancer. Immunotherapy, 2013, 5, 533-545.	2.0	31
104	Natural and Induced T Regulatory Cells in Cancer. Frontiers in Immunology, 2013, 4, 190.	4.8	202
105	Overcoming regulatory T cell suppression by a lyophilized preparation of <i>Streptococcus pyogenes</i> . European Journal of Immunology, 2013, 43, 989-1000.	2.9	8
106	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood, 2012, 119, 3097-3104.	1.4	65
107	Tax is a potential molecular target for immunotherapy of adult T cell leukemia/lymphoma. Cancer Science, 2012, 103, 1764-1773.	3.9	23
108	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor $\beta 2$ chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy, 2012, 14, 733-742.	0.7	56

#	ARTICLE	IF	CITATIONS
109	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. <i>Cancer Research</i> , 2012, 72, 1672-1682.	0.9	46
110	Human bone marrow stromal cells simultaneously support <scp>B</scp> and <scp>T</scp>/<scp>NK</scp> lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. <i>British Journal of Haematology</i> , 2012, 157, 674-686.	2.5	12
111	Heteroclitic serological response in esophageal and prostate cancer patients after NYâ€€ESOâ€€1 protein vaccination. <i>International Journal of Cancer</i> , 2012, 130, 584-592.	5.1	38
112	UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. <i>International Journal of Cancer</i> , 2011, 129, 1126-1136.	5.1	19
113	NYâ€€COâ€€58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. <i>International Journal of Cancer</i> , 2010, 127, 381-393.	5.1	52
114	Regulatory T cells in tumor immunity. <i>International Journal of Cancer</i> , 2010, 127, 759-767.	5.1	749
115	Thioredoxin suppresses airway inflammation independently of systemic Th1/Th2 immune modulation. <i>European Journal of Immunology</i> , 2010, 40, 787-796.	2.9	37
116	Tumorâ€€infiltrating ILâ€€17â€€producing Î³Î³ T cells support the progression of tumor by promoting angiogenesis. <i>European Journal of Immunology</i> , 2010, 40, 1927-1937.	2.9	200
117	NYâ€€ESOâ€€1 protein glycosylated by yeast induces enhanced immune responses. <i>Yeast</i> , 2010, 27, 919-931.	1.7	5
118	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. <i>Clinical Cancer Research</i> , 2010, 16, 2781-2791.	7.0	118
119	Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells. <i>Journal of Immunology</i> , 2010, 185, 3768-3776.	0.8	47
120	IFN-Î³-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. <i>Carcinogenesis</i> , 2009, 30, 1408-1415.	2.8	33
121	Glucocorticoidâ€€induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigenâ€€specific CD8⁺ T cells with tumor regression. <i>Cancer Science</i> , 2009, 100, 1317-1325.	3.9	34
122	Regulatory T Cellâ€€Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. <i>Cancer Research</i> , 2008, 68, 5948-5954.	0.9	80
123	Induction of regulatory T cellâ€€resistant helper CD4+ T cells by bacterial vector. <i>Blood</i> , 2008, 111, 1404-1412.	1.4	28
124	NYâ€€ESOâ€€1: Review of an Immunogenic Tumor Antigen. <i>Advances in Cancer Research</i> , 2006, 95, 1-30.	5.0	311
125	De novo CD5-positive Diffuse Large B-cell Lymphoma of the Temporal Bone Presenting with an External Auditory Canal Tumor. <i>Internal Medicine</i> , 2006, 45, 733-737.	0.7	19
126	Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination. <i>Journal of Immunology</i> , 2006, 176, 6340-6346.	0.8	52

#	ARTICLE	IF	CITATIONS
127	In vivo antigen delivery by a <i>Salmonella typhimurium</i> type III secretion system for therapeutic cancer vaccines. <i>Journal of Clinical Investigation</i> , 2006, 116, 1946-1954.	8.2	164
128	CD4 ⁺ CD25 ⁺ regulatory T cells control the induction of antigen-specific CD4 ⁺ helper T cell responses in cancer patients. <i>Blood</i> , 2005, 106, 1008-1011.	1.4	160
129	Intraepithelial CD8 ⁺ tumor-infiltrating lymphocytes and a high CD8 ⁺ /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18538-18543.	7.1	2,100
130	Accelerated chemically induced tumor development mediated by CD4 ⁺ CD25 ⁺ regulatory T cells in wild-type hosts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9253-9257.	7.1	102
131	IFN- γ Controls the Generation/Activation of CD4 ⁺ CD25 ⁺ Regulatory T Cells in Antitumor Immune Response. <i>Journal of Immunology</i> , 2005, 175, 4433-4440.	0.8	92
132	Definition of target antigens for naturally occurring CD4 ⁺ CD25 ⁺ regulatory T cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 681-686.	8.5	118
133	Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes. <i>American Journal of Hematology</i> , 2004, 75, 179-189.	4.1	25
134	CD4 ⁺ CD25 ⁺ T cells responding to serologically defined autoantigens suppress antitumor immune responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10902-10906.	7.1	152
135	The Soluble Notch Ligand, Jagged-1, Inhibits Proliferation of CD34 ⁺ Macrophage Progenitors. <i>International Journal of Hematology</i> , 2002, 75, 269-276.	1.6	40
136	Efficient ex vivo generation of dendritic cells from CD14 ⁺ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. <i>British Journal of Haematology</i> , 2001, 114, 681-689.	2.5	22